118 related articles for article (PubMed ID: 7541492)
1. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system.
Zajicek J; Wing M; Skepper J; Compston A
Lab Invest; 1995 Jul; 73(1):128-38. PubMed ID: 7541492
[TBL] [Abstract][Full Text] [Related]
2. The expression of CD59 in normal human nervous tissue.
Vedeler C; Ulvestad E; Bjørge L; Conti G; Williams K; Mørk S; Matre R
Immunology; 1994 Aug; 82(4):542-7. PubMed ID: 7530684
[TBL] [Abstract][Full Text] [Related]
3. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis.
Brooimans RA; Van der Ark AA; Tomita M; Van Es LA; Daha MR
Eur J Immunol; 1992 Mar; 22(3):791-7. PubMed ID: 1372260
[TBL] [Abstract][Full Text] [Related]
4. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
5. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.
Scolding NJ; Morgan BP; Houston WA; Linington C; Campbell AK; Compston DA
Nature; 1989 Jun; 339(6226):620-2. PubMed ID: 2733792
[TBL] [Abstract][Full Text] [Related]
6. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
Capey S; van den Berg CW
Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
[TBL] [Abstract][Full Text] [Related]
7. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement.
Walsh LA; Tone M; Waldmann H
Eur J Immunol; 1991 Mar; 21(3):847-50. PubMed ID: 1707009
[TBL] [Abstract][Full Text] [Related]
8. A new oligodendrocyte specific plasma membrane surface protein identified by a monoclonal antibody produced in vitro.
Birling MC; Nussbaum F; Nussbaum JL
J Neurosci Res; 1994 Aug; 38(5):538-50. PubMed ID: 7815472
[TBL] [Abstract][Full Text] [Related]
9. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis.
Piddlesden SJ; Morgan BP
J Neuroimmunol; 1993; 48(2):169-75. PubMed ID: 7693753
[TBL] [Abstract][Full Text] [Related]
10. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.
Wing MG; Zajicek J; Seilly DJ; Compston DA; Lachmann PJ
Immunology; 1992 May; 76(1):140-5. PubMed ID: 1378423
[TBL] [Abstract][Full Text] [Related]
11. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
Chen S; Caragine T; Cheung NK; Tomlinson S
Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.
Tedesco F; Narchi G; Radillo O; Meri S; Ferrone S; Betterle C
J Immunol; 1993 Aug; 151(3):1562-70. PubMed ID: 7687635
[TBL] [Abstract][Full Text] [Related]
13. Effects of complement activation on the expression of CD59 by human mesangial cells.
Shibata T; Kohsaka T
J Immunol; 1995 Jul; 155(1):403-9. PubMed ID: 7541422
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
15. Anti-heat shock protein 90beta antibodies decrease pre-oligodendrocyte population in perinatal and adult cell cultures. Implications for remyelination in multiple sclerosis.
Cid C; Alvarez-Cermeño JC; Salinas M; Alcázar A
J Neurochem; 2005 Oct; 95(2):349-60. PubMed ID: 16135098
[TBL] [Abstract][Full Text] [Related]
16. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
17. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
18. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
19. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
20. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis.
Omari KM; John GR; Sealfon SC; Raine CS
Brain; 2005 May; 128(Pt 5):1003-15. PubMed ID: 15774504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
